These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11227673)

  • 21. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
    Yeh CT; Chien RN; Chu CM; Liaw YF
    Hepatology; 2000 Jun; 31(6):1318-26. PubMed ID: 10827158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus resistance to lamivudine and its clinical implications.
    Liu X; Schinazi RF
    Antivir Chem Chemother; 2002 May; 13(3):143-55. PubMed ID: 12448687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic hepatitis B, biological basis for new therapeutic strategies.
    Dianzani F
    J Biol Regul Homeost Agents; 1999; 13(2):71-9. PubMed ID: 10503729
    [No Abstract]   [Full Text] [Related]  

  • 25. [YMDD motif and its significance].
    Goto T; Kato N; Omata M
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():46-50. PubMed ID: 15453283
    [No Abstract]   [Full Text] [Related]  

  • 26. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.
    Allen MI; Deslauriers M; Andrews CW; Tipples GA; Walters KA; Tyrrell DL; Brown N; Condreay LD
    Hepatology; 1998 Jun; 27(6):1670-7. PubMed ID: 9620341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
    Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
    Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions.
    Aberle SW; Kletzmayr J; Watschinger B; Schmied B; Vetter N; Puchhammer-Stöckl E
    J Clin Microbiol; 2001 May; 39(5):1972-4. PubMed ID: 11326026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.
    Liu Y; Wang C; Zhong Y; Chen L; Li X; Ji D; Wang H; Xin S; Zoulim F; Xu D
    Antivir Ther; 2010; 15(8):1185-90. PubMed ID: 21149926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.
    Jardi R; Buti M; Rodriguez-Frias F; Cotrina M; Costa X; Pascual C; Esteban R; Guardia J
    J Virol Methods; 1999 Dec; 83(1-2):181-7. PubMed ID: 10598095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B virus genotypic resistance to lamivudine.
    Fontaine H; Thiers V; Pol S
    Ann Intern Med; 1999 Nov; 131(9):716-7. PubMed ID: 10577345
    [No Abstract]   [Full Text] [Related]  

  • 32. [New antiviral agent. Hepatitis B therapy with slight resistance risk].
    MMW Fortschr Med; 2003 Dec; 145(51-52):40. PubMed ID: 14974332
    [No Abstract]   [Full Text] [Related]  

  • 33. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
    Yatsuji H; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Abe H; Maekawa T; Tateno C; Yoshizato K; Suzuki F; Kumada H; Chayama K
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3867-74. PubMed ID: 16982790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous detection of two major lamivudine-resistant mutants using competitively differentiated-PCR.
    Peng XM; Gu L; Huang YS; Ma HH; Xie QF; Li G; Gao ZL
    J Virol Methods; 2005 Sep; 128(1-2):168-75. PubMed ID: 15950294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.
    Ling R; Harrison TJ
    J Gen Virol; 1999 Mar; 80 ( Pt 3)():601-606. PubMed ID: 10091998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lamivudine resistance in hepatitis B: mechanisms and clinical implications.
    Fischer KP; Gutfreund KS; Tyrrell DL
    Drug Resist Updat; 2001 Apr; 4(2):118-28. PubMed ID: 11512520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance in antiviral therapy.
    Locarnini S; Bowden S
    Clin Liver Dis; 2010 Aug; 14(3):439-59. PubMed ID: 20638024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF
    Antivir Chem Chemother; 2001; 12 Suppl 1():67-71. PubMed ID: 11594691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A study on the treatment of chronic hepatitis B with YMDD mutation].
    Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.